Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Panel Reactive Antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Panel Reactive Antibody. Displaying page 1 of 1.
    EudraCT Number: 2015-005346-58 Sponsor Protocol Number: RIMINI Start Date*: 2016-10-05
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)
    Medical condition: Rejection rate, graft loss or poor graft function defined as eGFR<40 ml/min in patients with kidney transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005961-16 Sponsor Protocol Number: QVID-001 Start Date*: 2021-02-05
    Sponsor Name:Lars Jørgen Østergaard
    Full Title: Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study)
    Medical condition: Long Term COVID-19 illness
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001352-19 Sponsor Protocol Number: 20120309-01 Start Date*: 2012-10-15
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections
    Medical condition: Kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004558-44 Sponsor Protocol Number: 2021-00604 Start Date*: 2021-10-10
    Sponsor Name:UMCG
    Full Title: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients
    Medical condition: COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 100000004865 10084464 COVID-19 immunization LLT
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    23.1 10022891 - Investigations 10084508 COVID-19 antibody test LLT
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    20.0 100000004865 10023438 Kidney transplant LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    23.0 100000004865 10084463 SARS-CoV-2 immunisation LLT
    23.0 100000004865 10084466 SARS-CoV-2 immunization LLT
    23.1 10022891 - Investigations 10084501 SARS-CoV-2 antibody test PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000242-30 Sponsor Protocol Number: CNTO148PSA3001 Start Date*: 2014-12-29
    Sponsor Name:Janssen Biologics, BV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects with Active Psoriatic Arthritis
    Medical condition: Psoriatic Arthritis (PsA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-004956-39 Sponsor Protocol Number: SMART-DSA Start Date*: 2014-06-18
    Sponsor Name:Klinikum der Universität München
    Full Title: Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population
    Medical condition: Renal Transplantation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004154-28 Sponsor Protocol Number: TED16414 Start Date*: 2020-04-20
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 1b/2 study to evaluate the safety, pharmacokinetics, and preliminary efficacy of isatuximab (SAR650984) in patients awaiting kidney transplantation
    Medical condition: (Patients awaiting) kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021425 Immune system disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003296-34 Sponsor Protocol Number: OTX116505 Start Date*: 2014-01-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli...
    Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10003814 Autoimmune disease, not elsewhere classified LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002202-31 Sponsor Protocol Number: BAT-1806-002-CR Start Date*: 2019-03-27
    Sponsor Name:Bio-Thera Solutions, Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
    Medical condition: Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-004101-33 Sponsor Protocol Number: 0468E-102362 Start Date*: 2015-04-07
    Sponsor Name:Wyeth Korea, Inc.
    Full Title: A Clinical Study to Evaluate the Efficacy and Safety of Cyclosporine (CsA) and Sirolimus (SRL) Induction Followed by Cyclosporine Withdrawal in Korean Renal Allograft Recipients
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-012673-35 Sponsor Protocol Number: PHAO08-YL/THYMO Start Date*: 2009-07-03
    Sponsor Name:CHRU de TOURS
    Full Title: Etude pharmacocinétique et pharmacodynamique comparant deux posologies différentes de la Thymoglobuline® en transplantation rénale.
    Medical condition: Renal transplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000497-80 Sponsor Protocol Number: H7U-MC-IDAV Start Date*: 2007-07-27
    Sponsor Name:Eli Lilly and Company Ltd
    Full Title: A Phase 3, Open-Label, Parallel-Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder (HIIP) Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabete...
    Medical condition: Male or female nonsmoking patients 18 years of age or older who have had type 1 diabetes mellitus for at least 24 months at study entry and are taking at least 2 or 3 preprandial injections per day...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000561-33 Sponsor Protocol Number: TOL-2 Start Date*: 2022-03-08
    Sponsor Name:TolerogenixX GmbH
    Full Title: An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-ca...
    Medical condition: Living donor kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001455-39 Sponsor Protocol Number: OPN-305-102 Start Date*: 2012-10-10
    Sponsor Name:Opsona Therapeutics Ltd
    Full Title: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanis...
    Medical condition: Prevention of Kidney Graft Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004863 10051366 Kidney graft dysfunction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) GB (Completed) CZ (Completed) AT (Completed) ES (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004225-24 Sponsor Protocol Number: CNTO1275CRD3004 Start Date*: 2021-03-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of the Efficacy, Safety, and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance i...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) BE (Ongoing) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-004224-38 Sponsor Protocol Number: CNTO1275PUC3001 Start Date*: 2021-02-25
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) Outside EU/EEA BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA